Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in adults aged over 50 years in developed countries. In 2006, the use of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs revolutionised the therapeutic approach to treating neovascular AMD. However, it is essential to detect the frequent diagnostic pitfalls encountered in this therapeutic domain to apply anti-VEGF therapy successfully and thereby avoid useless treatments. Classic pitfalls include -retinal pigmented epithelium-photoreceptor abnormalities mimicking choroidal neovascularisation; persistent serous retinal detachment; pseudocysts and cystoid cavities mimicking retinal oedema; and outer retinal tubulations. Current imaging technologies, such as colour fundus photography, autofluorescence (FAF) and infrared imaging, fluorescein (FA) and indocyanine green (ICGA) angiographies, spectral domain optical coherence tomography (SD-OCT) and enhanced depth imaging OCT (EDI-OCT), can help overcome these pitfalls. Even if anti-VEGF treatments are mostly based on SD-OCT data, the consolidation and correlational analysis of all the available patient data is essential for accurate diagnosis.
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in adults aged over 50 years in developed countries 1, 2 and, given the ageing of the populations of these countries, its prevalence is likely to increase dramatically over the coming years. 3, 4 Several ocular diseases, including exudative AMD, are characterised by new choroidal vessel formation leading, if untreated, to severe vision loss. Current knowledge of AMD pathogenesis has contributed to the development of new treatment modalities. Vascular endothelial growth factor (VEGF) has a key role in promoting angiogenesis and vascular leakage in exudative AMD. 5, 6 All retinal cells can be damaged, provoking specific intraretinal anomalies that can now be detected owing to the different imaging techniques currently available.
The era of pathway-based therapy for the early and late stages of AMD has begun, 7 but anti-VEGF drugs in wet AMD, according to the most important randomised clinical trials, [8] [9] [10] [11] [12] are still the only therapeutic modality that can regress neovascularisation. Currently, patients with exudative AMD are treated according to the recommendations of these clinical trials. Thus, the patients benefit from repeated intravitreal injections of anti-VEGF drugs and regular follow-up to evaluate their neovascular activity. The latter is based on interpreting SD-OCT images along with filter photographs, angiography and biomicroscopy findings.
Neovascular formation is also accompanied by an influx of inflammatory cells, followed by fibroblast formation that leads to fibroglial scarring. 13 This phenomenon can be observed despite the administration of anti-VEGF drugs. Overcoming the various diagnostic pitfalls is undoubtedly the key to arriving at the best therapeutic decision.
Anti-Vascular Endothelial Growth Factor Treatment Guidelines
Anti-VEGF treatment guidelines are based on the interpretation of high-resolution OCT imaging and on improved angiography imaging thanks to confocal systems and eye trackers. However, interpreting these examinations alone, without taking into account the clinical aspect, can lead to numerous diagnostic mistakes or inaccuracies.
Thus, the examination and comparison of these data with the results of clinical examination is essential.
sometimes be used to interpret wrongly a mechanism of chronic retinal degeneration as neovascular activity.
Classic Pitfalls
Classic pitfalls encountered during anti-VEGF treatment are:
• retinal pigment epithelium (RPE)-photoreceptor abnormalities mimicking active choroidal neovascularisation (CNV);
• persistent serous retinal detachment;
• pseudocysts and cystoid cavities mimicking retinal oedema; and
• outer retinal tubulations. Clinically, three distinct types of AVL can be detected, all mimicking CNV activity:
• Type 1 14 -AVL can present as a pseudo-serous retinal detachment with vitelliform material (see Figure 1A It is important to correlate the hyperautofluorescent areas seen in FAF with the OCT scans to identify the subretinal material above 
Type 1 -A: fundus autofluorescence (FAF) demonstrates hyperautofluorescence; B: corresponding FAF spectral domain optical coherence tomography (SD-OCT) shows fragmented vitelliform lesion (arrows) and pseudosubretinal fluid (arrow heads) at the superior edge of the acquired vitelliform lesions (AVL). Type 2 -C: fluorescein angiogram with D, corresponding SD-OCT showing hyper-reflective material in the subretinal space (arrow heads) and focal thickening (or bumps) of the retinal pigment epithelium (RPE) band (arrows). Type 3 -E: FAF showing a hyperautofluorescent lesion; F: hyper-reflective material (arrows) in the subretinal space overlying a serous retinal pigment epithelium detachment.
the RPE. This material is represented as a heterogenous reflective tissue between the RPE line and the inner segment-outer segment (IS/OS) photoreceptor junction line. It is often useful to magnify the SD-OCT image so as to verify that the RPE band is intact and that the serous retinal detachment observed corresponds to material resorption.
• Type 2 -multimodal imaging in eyes with AVL has identified a second distinct type of material within the subretinal space (see Figure 1C and D • Type 3 -(see Figure 1E and F) type 3 AVL is less frequent, 
Pitfall 2 -Persistent Serous Detachment During Anti-Vascular Endothelial Growth Factor Treatment
There are two main pitfalls in the case of persistent serous detachment during anti-VEGF treatment -general RPE dysfunction and polypoidal vasculopathy.
• General RPE dysfunction. In some cases, after a period of active 
Spectral domain optical coherence tomography (SD-OCT) shows serous retinal fluid, focal thickening of the retinal pigment epithelium (RPE) and cystoid cavities (B). Enhanced depth imaging (EDI)-OCT demonstrates increased choroidal thickness (arrow) (C). Corresponding indocyanine green angiography (ICGA) demonstrates inner choroidal staining in the midstage of angiogram (A).

Figure 3: Retinal Pseudocysts
A B
Retinal pseudocysts (here after drusen resorption) (arrow) are located in the inner nuclear layer (A) above a hypoautofluorescent retinal pigment epithelium (RPE) atrophic area (B).
• Polypoidal vasculopathy. A false anti-VEGF resistance with persistent serous retinal detachment can occur in the case of polypoidal vasculopathy; this condition usually needs combination treatment for a better outcome.
It is particularly important to know that neovascular AMD that is refractory to a course of anti-VEGF monotherapy can harbour polypoidal choroidal vasculopathy. 17 Polypoidal dilations might be suspected on SD-OCT, but ICGA is the most valuable tool for revealing polypoidal lesions. In this pathology, it is recommended to combine the angio-occlusion of the polyps using photodynamic therapy and the anti-permeability effect of anti-VEGF therapy on the branching vascular network.
Pitfall 3 -Pseudocysts and Cystoid Cavities
When a patient presents with intraretinal cysts during anti-VEGF treatment, the question is whether they are a sign of either exudation or degeneration? The cysts can be seen during routine AMD examination or during anti-VEGF treatment. Cohen et al. 18 described hyporeflective cavities, located mainly in the internal nuclear layer but also in all other retinal layers, in dry AMD. He named these degenerative lesions 'retinal pseudocysts'. These lesions have no walls and differ from retinal oedema in lacking retinal thickening. They are always located near an area of RPE atrophy (see Figure 3) . They have no angiographic signs and can be found in 27 % of cases of geographical atrophy. They can also be seen during drusen resorption and are mostly found in the outer plexiform layer. The evolution of drusen has successive phases with first, an increase in drusen material and alteration of the surrounding tissues, followed by a disruption of the drusen, which is replaced by an atrophic area that can be correlated with pseudocysts.
The reason why such abnormalities develop is still not completely understood. Pseudocysts could correspond to Müller cell degeneration as seen in idiopathic macular telangiectasia type 2A and tamoxifen retinopathy. Anti-VEGF intravitreal injections have no effect on these cavities, which do not seem to be modified with time.
Pseudocystic lesions, similar to those found in geographical atrophy, were described by Querques et al. 19 
Pitfall 4 -Outer Retinal Tubulations
Outer retinal tubulations (see Figure 4 ) can be seen in both atrophic and exudative AMD. On B-scan SD-OCT, the outer tubulations are usually round, but they can also be elongated in shape, resembling a serous retinal detachment, in which case they have to be distinguished from CNV activity.
Zweifel et al. 21 were the first to describe this aspect of retinal 
Conclusion
In conclusion, even if anti-VEGF treatments are based on SD-OCT data, the discussed pitfalls must be taken into consideration. An overall analysis of the patient's clinical examination, together with the imaging findings, is essential for accurate diagnosis and treatment of AMD. n 
